rapid development multidisciplinary field tissue engineering resulted variety new innovative medicinal products often carrying living cells intended repair regenerate replace damaged human tissue tissue engineered medicinal products temps vary terms type origin cells product complexity medicinal products safety efficacy temps must consistent throughout manufacturing process quality control assurance paramount importance products constantly assessed throughout manufacturing process ensure safety efficacy consistency reproducibility european medicines agency ema responsible development assessment supervision medicines eu appointed committees involved referral procedures concerning safety balance benefitrisk medicinal product addition committees organize inspections regards conditions medicinal products manufactured example compliance good manufacturing practice gmp good clinical practice gcp good laboratory practice glp pharmacovigilance quality control temps considered risk assessment needs conducted risk defined potentially unfavourable effect attributed clinical use advanced therapy medicinal products atmps concern patient andor populations eg caregivers risks include immunogenicity disease transmission tumor formation treatment failure undesirable tissue formation inadvertent germ transduction risk factor defined qualitative quantitative characteristic contributes specific risk following handling andor administration integration available information risks risk factors called risk profiling due fact every temp different risks associated one vary subsequently procedures must implemented ensure quality also unique product risks associated temp identified appropriate tests must developed validated accordingly thus standard set tests quality control temps ema released set regulatory guidelines topics considered companies involved development marketing medicines use european guidelines followed order marketing authorization product issued fictitious examples risk analysis elucidation process provided ema careful detailed documentation concerning characteristics starting materials eg history cell line derivation cell banking manufacturing process steps eg procurement tissue cells manipulation must maintained cellular part every cellbased medicinal product must characterized terms identity purity potency viability suitability intended use noncellular constituents must also characterized regards intended function final product example scaffolds membranes used support cells must identified characterized terms porosity density microscopic structure particular size requirement characterization applies biologically active molecules growth factors proper quality control involves release testing final product updated validated methods release specifications product must selected basis parameters defined characterization studies appropriate release tests must performed case release test performed final product previous stages manufacturing exceptions made proper justification however cases adequate quality control rise manufacturing process specifications stability product presence genetically modified cells structural components whether combination product must also httpsenwikipediaorgwikiqualitycontrolintissueengineering